Systematic Discovery of Ectopic Pregnancy Serum Biomarkers Using 3-D Protein Profiling Coupled with Label-free Quantitation

• Published in: Journal of proteome research 2011-03, Vol.10 (3), p.1126-1138
• Main Authors: Beer, Lynn A, Tang, Hsin-Yao, Sriswasdi, Sira, Barnhart, Kurt T, Speicher, David W
• Format: Article
• Language: English
• Subjects: ADAM Proteins - blood; ADAM Proteins - genetics; ADAM12 Protein; Amino Acid Sequence; Biomarkers - blood; Blood Proteins - analysis; Chromatography, Liquid - methods; Databases, Protein; Electrophoresis, Polyacrylamide Gel - methods; Female; Humans; Membrane Proteins - blood; Membrane Proteins - genetics; Molecular Sequence Data; Pregnancy - blood; Pregnancy, Ectopic - blood; Proteome - analysis; Proteomics - methods; Tandem Mass Spectrometry - methods
• ISSN: 1535-3893; 1535-3907
• DOI: 10.1021/pr1008866

Ectopic pregnancy (EP) and normal intrauterine pregnancy (IUP) serum proteomes were quantitatively compared to systematically identify candidate biomarkers. A 3-D biomarker discovery strategy consisting of abundant protein immunodepletion, SDS gels, LC−MS/MS, and label-free quantitation of MS signal intensities identified 70 candidate biomarkers with differences between groups greater than 2.5-fold. Further statistical analyses of peptide quantities were used to select the most promising 12 biomarkers for further study, which included known EP biomarkers, novel EP biomarkers (ADAM12 and ISM2), and five specific isoforms of the pregnancy specific beta-1-glycoprotein family. Technical replicates showed good reproducibility and protein intensities from the label-free discovery analysis compared favorably with reported abundance levels of several known reference serum proteins over at least 3 orders of magnitude. Similarly, relative abundances of candidate biomarkers from the label-free discovery analysis were consistent with relative abundances from pilot validation assays performed for five of the 12 most promising biomarkers using label-free multiple reaction monitoring of both the patient serum pools used for discovery and the individual samples that constituted these pools. These results demonstrate robust, reproducible, in-depth 3-D serum proteome discovery, and subsequent pilot-scale validation studies can be achieved readily using label-free quantitation strategies.